U.S., March 3 -- ClinicalTrials.gov registry received information related to the study (NCT07442513) titled 'Comparison of Etamsylate Versus Placebo to Prevent Bleeding in HSCT' on Feb. 25.
Brief Summary: This study employs a prospective, randomized, double-blind, placebo-controlled design. It aims to compare the efficacy of etamsylate versus placebo in preventing bleeding complications in patients with thrombocytopenia following hematopoietic stem cell transplantation.
Study Start Date: Dec. 16, 2025
Study Type: INTERVENTIONAL
Condition:
Hematopoietic Stem Cell Transplantation
Thrombocytopenia
Intervention:
DRUG: etamsylate
etamsylate Injection, administer by intravenous infusion, diluted with 100ml of 0.9% Sodium Chloride Injectio...